{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T10:31:35Z","timestamp":1776335495338,"version":"3.51.2"},"reference-count":51,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,12,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Von Willebrand factor (VWF) is a critical regulator of hemostatic processes, including collagen binding, platelet adhesion, and platelet aggregation. It also serves as a carrier protein to normalize plasma factor VIII synthesis, release, and survival. While VWF protein measurements by immunoassay are reasonably comparable between institutions, the measurement of VWF ristocetin cofactor activity (VWF:RCo) has significant variability. Other tests of VWF function, including collagen binding or platelet glycoprotein IIb-IIIa binding, are not universally available, yet these functional defects may cause major bleeding even with normal VWF antigen (VWF:Ag) and VWF:RCo assays. This results in both the overdiagnosis and underdiagnosis of VWD. Newer assays of VWF function (using recombinant glycoprotein Ib rather than whole platelets) have been developed that may improve interlaboratory variability. Some of these tests are not uniformly available and may not be licensed in the United States. Large longitudinal studies of VWF in von Willebrand disease (VWD) patients are not available. Patients are sometimes diagnosed with a single diagnostic VWF panel. Plasma VWF levels increase with age, but it is not clear if this results in less bleeding or whether different normal ranges should be used to identify age-related decreases in VWF. In order to quantitatively compare bleeding symptoms in VWD patients and normal individuals, recent studies in the European Union, Canada, United Kingdom, Holland, and the United States have used semiquantitative bleeding assessment tools (BATs). Even with careful centralized testing, including functional assays of VWF, addition of a BAT does not solve all of the problems with VWD diagnosis. No matter where the line is drawn for diagnosis of VWD, VWF is still a continuous variable. Thus, VWD can be a severe hemorrhagic disease requiring frequent treatment or a mild condition that may not be clinically relevant. As will be discussed by Dr. Goodeve in her presentation, genetics has helped us to diagnose type 2 functional variants of VWD but has not been helpful for the many patients who are at the interface of normal and low VWF and carry the possible diagnosis of type 1 VWD. The hematologist\u2019s management of patients with reduced levels of VWF still requires both the art and science of clinical medicine.<\/jats:p>","DOI":"10.1182\/asheducation-2016.1.670","type":"journal-article","created":{"date-parts":[[2016,12,2]],"date-time":"2016-12-02T16:05:27Z","timestamp":1480694727000},"page":"670-677","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":9,"title":["What have we learned from large population studies of von Willebrand disease?"],"prefix":"10.1182","volume":"2016","author":[{"given":"Robert R.","family":"Montgomery","sequence":"first","affiliation":[{"name":"Blood Research Institute, BloodCenter of Wisconsin and Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica H.","family":"Flood","sequence":"additional","affiliation":[{"name":"Blood Research Institute, BloodCenter of Wisconsin and Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"1","key":"2019111703093207400_B1","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood-2006-05-020784","article-title":"Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD)","volume":"109","author":"Goodeve","year":"2007","journal-title":"Blood"},{"issue":"1","key":"2019111703093207400_B2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1182\/blood-2006-05-021105","article-title":"The mutational spectrum of type 1 von Willebrand disease: Results from a Canadian cohort study","volume":"109","author":"James","year":"2007","journal-title":"Blood"},{"issue":"5","key":"2019111703093207400_B3","first-page":"630","article-title":"An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type 1 von Willebrand disease","volume":"96","author":"Cumming","year":"2006","journal-title":"Thromb Haemost"},{"issue":"3","key":"2019111703093207400_B4","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/j.1538-7836.2010.04175.x","article-title":"Impact of von Willebrand disease on health-related quality of life in a pediatric population","volume":"9","author":"de Wee","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"20","key":"2019111703093207400_B5","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1182\/blood-2015-10-673681","article-title":"Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States","volume":"127","author":"Flood","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2019111703093207400_B6","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.blre.2014.03.001","article-title":"Desmopressin in treatment of haematological disorders and in prevention of surgical bleeding","volume":"28","author":"Svensson","year":"2014","journal-title":"Blood Rev"},{"issue":"8","key":"2019111703093207400_B7","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1111\/j.1538-7836.2005.01369.x","article-title":"von Willebrand factor: two sides of a coin","volume":"3","author":"Sadler","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"10","key":"2019111703093207400_B8","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1111\/j.1538-7836.2004.00933.x","article-title":"Slippery criteria for von Willebrand disease type 1","volume":"2","author":"Sadler","year":"2004","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2019111703093207400_B9","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1182\/blood-2002-09-2892","article-title":"Von Willebrand disease type 1: a diagnosis in search of a disease","volume":"101","author":"Sadler","year":"2003","journal-title":"Blood"},{"issue":"2","key":"2019111703093207400_B10","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1182\/blood-2009-10-249102","article-title":"Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor","volume":"116","author":"Flood","year":"2010","journal-title":"Blood"},{"issue":"11","key":"2019111703093207400_B11","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1111\/j.1538-7836.2009.03594.x","article-title":"Limitations of the ristocetin cofactor assay in measurement of von Willebrand factor function","volume":"7","author":"Flood","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2019111703093207400_B12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/ajh.1090","article-title":"Population differences in von Willebrand factor levels affect the diagnosis of von Willebrand disease in African-American women","volume":"67","author":"Miller","year":"2001","journal-title":"Am J Hematol"},{"issue":"6","key":"2019111703093207400_B13","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1182\/blood-2010-08-299016","article-title":"Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD","volume":"117","author":"Flood","year":"2011","journal-title":"Blood"},{"issue":"6","key":"2019111703093207400_B14","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1182\/blood.V69.6.1691.1691","article-title":"The effect of ABO blood group on the diagnosis of von Willebrand disease","volume":"69","author":"Gill","year":"1987","journal-title":"Blood"},{"key":"2019111703093207400_B15","doi-asserted-by":"crossref","DOI":"10.1111\/jth.13294","article-title":"Aging and ABO blood type influence VWF and FVIII levels through interrelated mechanisms","author":"Albanez","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2019111703093207400_B16","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1046\/j.1365-3148.2001.00315.x","article-title":"The relationship between ABO histo-blood group, factor VIII and von Willebrand factor","volume":"11","author":"O\u2019Donnell","year":"2001","journal-title":"Transfus Med"},{"issue":"10","key":"2019111703093207400_B17","doi-asserted-by":"crossref","first-page":"4979","DOI":"10.1182\/blood-2007-09-110940","article-title":"Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD)","volume":"111","author":"Haberichter","year":"2008","journal-title":"Blood"},{"issue":"10","key":"2019111703093207400_B18","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1182\/blood-2006-04-015065","article-title":"Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival","volume":"108","author":"Haberichter","year":"2006","journal-title":"Blood"},{"issue":"19","key":"2019111703093207400_B19","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1182\/blood-2015-03-629832","article-title":"VWF propeptide in defining VWD subtypes","volume":"125","author":"Haberichter","year":"2015","journal-title":"Blood"},{"issue":"5","key":"2019111703093207400_B20","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/j.1538-7836.2012.04672.x","article-title":"Standardization of von Willebrand factor propeptide: value assignment to the WHO 6th IS Factor VIII\/von Willebrand factor, plasma (07\/316)","volume":"10","author":"Hubbard","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"7","key":"2019111703093207400_B21","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s00415-014-7362-3","article-title":"Longitudinal assessment of von Willebrand factor antigen and von Willebrand factor propeptide in response to alteration of antiplatelet therapy after TIA or ischaemic stroke","volume":"261","author":"Tobin","year":"2014","journal-title":"J Neurol"},{"issue":"7","key":"2019111703093207400_B22","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/ene.12403","article-title":"Increased endothelial activation in recently symptomatic versus asymptomatic carotid artery stenosis and in cerebral microembolic-signal-negative patient subgroups","volume":"21","author":"Kinsella","year":"2014","journal-title":"Eur J Neurol"},{"issue":"5","key":"2019111703093207400_B23","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/j.1365-2141.2006.06067.x","article-title":"von Willebrand factor propeptide in malaria: evidence of acute endothelial cell activation","volume":"133","author":"Hollestelle","year":"2006","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111703093207400_B24","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/ageing\/afp019","article-title":"Heyde syndrome: a common diagnosis in older patients with severe aortic stenosis","volume":"38","author":"Massyn","year":"2009","journal-title":"Age Ageing"},{"key":"2019111703093207400_B25","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.thromres.2016.01.016","article-title":"Increased bleeding risk in patients with aortic valvular stenosis: From new mechanisms to new therapies","volume":"139","author":"Natorska","year":"2016","journal-title":"Thromb Res"},{"issue":"11","key":"2019111703093207400_B26","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.5551\/jat.30809","article-title":"Unexpectedly high prevalence of acquired von Willebrand syndrome in patients with severe aortic stenosis as evaluated with a novel large multimer index","volume":"22","author":"Tamura","year":"2015","journal-title":"J Atheroscler Thromb"},{"issue":"3","key":"2019111703093207400_B27","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1182\/blood.V67.3.758.758","article-title":"Loss of the largest von Willebrand factor multimers from the plasma of patients with congenital cardiac defects","volume":"67","author":"Gill","year":"1986","journal-title":"Blood"},{"issue":"4","key":"2019111703093207400_B28","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1538-7836.2008.02917.x","article-title":"Acquired von Willebrand syndrome: is it an extremely rare disorder or do we see only the tip of the iceberg?","volume":"6","author":"Federici","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2019111703093207400_B29","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1055\/s-0038-1651577","article-title":"A database of polymorphisms in the von Willebrand factor gene and pseudogene","volume":"69","author":"Sadler","year":"1993","journal-title":"Thromb Haemost"},{"issue":"7","key":"2019111703093207400_B30","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1111\/j.1538-7836.2012.04746.x","article-title":"Critical von Willebrand factor A1 domain residues influence type VI collagen binding","volume":"10","author":"Flood","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"14","key":"2019111703093207400_B31","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1182\/blood-2014-11-610824","article-title":"Crucial role for the VWF A1 domain in binding to type IV collagen","volume":"125","author":"Flood","year":"2015","journal-title":"Blood"},{"issue":"4","key":"2019111703093207400_B32","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/hae.12117","article-title":"Variability in platelet- and collagen-binding defects in type 2M von Willebrand disease","volume":"19","author":"Larsen","year":"2013","journal-title":"Haemophilia"},{"issue":"7","key":"2019111703093207400_B33","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1111\/jth.12964","article-title":"Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH","volume":"13","author":"Bod\u00f3","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"8","key":"2019111703093207400_B34","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1097\/MBC.0000000000000169","article-title":"Performance evaluation and multicentre study of a von Willebrand factor activity assay based on GPIb binding in the absence of ristocetin","volume":"25","author":"Patzke","year":"2014","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"1","key":"2019111703093207400_B35","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1055\/s-0037-1614642","article-title":"New assay for measuring binding of platelet glycoprotein IIb\/IIIa to unpurified von Willebrand factor","volume":"82","author":"Veyradier","year":"1999","journal-title":"Thromb Haemost"},{"issue":"20","key":"2019111703093207400_B36","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1182\/blood-2015-11-664680","article-title":"Rapid discrimination of the phenotypic variants of von Willebrand disease","volume":"127","author":"Roberts","year":"2016","journal-title":"Blood"},{"issue":"12","key":"2019111703093207400_B37","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1111\/j.1538-7836.2005.01663.x","article-title":"The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study","volume":"3","author":"Rodeghiero","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2019111703093207400_B38","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/j.1538-7836.2006.01847.x","article-title":"A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD)","volume":"4","author":"Tosetto","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2019111703093207400_B39","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/j.1538-7836.2010.03796.x","article-title":"Quantitation of bleeding symptoms in children with von Willebrand disease: use of a standardized pediatric bleeding questionnaire","volume":"8","author":"Biss","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2019111703093207400_B40","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/hae.12503","article-title":"Normal range of bleeding scores for the ISTH-BAT: adult and pediatric data from the merging project","volume":"20","author":"Elbatarny","year":"2014","journal-title":"Haemophilia"},{"key":"2019111703093207400_B41","author":"Christopherson"},{"key":"2019111703093207400_B42","author":"Christopherson"},{"issue":"10","key":"2019111703093207400_B43","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.1172\/JCI77511","article-title":"Syntaxin-binding protein 5 exocytosis regulation: differential role in endothelial cells and platelets","volume":"124","author":"Lillicrap","year":"2014","journal-title":"J Clin Invest"},{"issue":"26","key":"2019111703093207400_B44","doi-asserted-by":"crossref","first-page":"5228","DOI":"10.1182\/blood-2012-10-457507","article-title":"The C-type lectin receptor CLEC4M binds, internalizes, and clears von Willebrand factor and contributes to the variation in plasma von Willebrand factor levels","volume":"121","author":"Rydz","year":"2013","journal-title":"Blood"},{"issue":"13","key":"2019111703093207400_B45","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1182\/blood-2014-06-528406","article-title":"von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends","volume":"125","author":"Lenting","year":"2015","journal-title":"Blood"},{"key":"2019111703093207400_B46","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/jth.12226","article-title":"Clearance of von Willebrand factor","volume":"11","author":"Casari","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"9","key":"2019111703093207400_B47","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1182\/blood-2011-08-373605","article-title":"Macrophage LRP1 contributes to the clearance of von Willebrand factor","volume":"119","author":"Rastegarlari","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2019111703093207400_B48","doi-asserted-by":"crossref","first-page":"e84810","DOI":"10.1371\/journal.pone.0084810","article-title":"Possible race and gender divergence in association of genetic variations with plasma von Willebrand factor: a study of ARIC and 1000 genome cohorts","volume":"9","author":"Zhou","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"2019111703093207400_B49","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/jth.12093","article-title":"Characterizing polymorphisms and allelic diversity of von Willebrand factor gene in the 1000 Genomes","volume":"11","author":"Wang","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2019111703093207400_B50","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2516.2007.01643.x","article-title":"von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA)","volume":"14","author":"Nichols","year":"2008","journal-title":"Haemophilia"},{"issue":"18","key":"2019111703093207400_B51","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1182\/blood-2015-04-639351","article-title":"Structural basis for quinine-dependent antibody binding to platelet integrin alphaIIbbeta3","volume":"126","author":"Zhu","year":"2015","journal-title":"Blood"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2016\/1\/670\/1251226\/hem088401.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2016\/1\/670\/1251226\/hem088401.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T05:01:27Z","timestamp":1692594087000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2016\/1\/670\/21102\/What-have-we-learned-from-large-population-studies"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,2]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12,2]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2016.1.670","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,2]]}}}